NCT06959888View on ClinicalTrials.gov

A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

May 8, 2025

Study Completion Date

May 16, 2025

Conditions
Healthy Volunteer Study
Interventions
DRUG

ALG-055009

"Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 1)~Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 2)"

Trial Locations (1)

78744

PPD Austin CRU, Austin

Sponsors
All Listed Sponsors
lead

Aligos Therapeutics

INDUSTRY

NCT06959888 - A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations | Biotech Hunter | Biotech Hunter